600521 华海药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.13313.18410.63116.558--
总资产报酬率 ROA (%)1.8375.7594.5196.947--
投入资产回报率 ROIC (%)2.1516.7995.3678.262--

边际利润分析
销售毛利率 (%)61.70561.91060.42362.36460.004
营业利润率 (%)8.66215.40513.53418.71813.071
息税前利润/营业总收入 (%)11.18716.33014.89518.12414.678
净利润/营业总收入 (%)5.83511.6009.83614.2287.235

收益指标分析
经营活动净收益/利润总额(%)79.497107.179110.133108.02943.574
价值变动净收益/利润总额(%)13.934-6.710-14.805-4.63956.798
营业外收支净额/利润总额(%)-1.093-0.491-2.201-2.536-10.353

偿债能力分析
流动比率 (X)1.3241.4201.4001.648--
速动比率 (X)0.7400.8480.7690.945--
资产负债率 (%)54.61855.48255.63957.328--
带息债务/全部投入资本 (%)41.58243.13843.06343.999--
股东权益/带息债务 (%)125.790120.051119.208112.754--
股东权益/负债合计 (%)82.31579.15278.04672.520--
利息保障倍数 (X)4.27216.3299.017-138.2855.182

营运能力分析
应收账款周转天数 (天)121.406102.260111.49498.3230.000
存货周转天数 (天)397.536338.832372.598353.7140.000